

Spread of Excellence update

F. Pane, F Cervantes, R. Hehlmann,
S. Saussele, L. Montrucchio, P. Schrotz-King,
A. Gratwohl, N. Gökbuget

Heidelberg, 5. July 2008

EUTOS for CML



European Treatment and Outcome Study

Overview

- Status update for Spread of Excellence
 - The project to date
 - Deliverables for the future
 - Next steps
- PR update
 - PR activities to date
 - PR plan for 2008

EUTOS for CML



European Treatment and Outcome Study

Objectives of SoE

- Raise awareness of the cooperation and Foster ELN activities
- Promote implementation of CML management recommendations
- Improve understanding and treatment of CML and enhance outcomes of CML across Europe and globally

EUTOS for CML



European Treatment and Outcome Study

General status update

EUTOS for CML



European Treatment and Outcome Study

Work plan – deliverables: planned milestones reached!

Deliverable	Delivery
Newsletter	Sept 07, July 08
Pocket card of ELN recommendations	Oct 07, June 08
Portal website opening	August 07
Website for SoE activities	August 07
Portal website filled with contain	Dec 07
Exhibition booth	Oct, Dec 07, June 08
Flyer	Dec 07
Posters	Dec 07
Scientific meetings	Oct 07, Jan 08, June 08, Oct 08
Update recommendations	Dec 08

EUTOS for CML



European Treatment and Outcome Study

Spread of Excellence to date

- Supportive materials created to date
 - ELN pocket card
 - EUTOS for CML included within ELN newsletter
 - Pharmacological Monitoring package finalized
 - EUTOS for CML core resource finalized
- Other supporting items created
 - ELN exhibition booth
 - Dedicated area within ELN website
- EUTOS FOR CML European event
 - 17-19th of October 2008, Cannes, France

EUTOS for CML



European Treatment and Outcome Study

Pharmacological Monitoring resource

- Introduction to EUTOS for CML Pharmacological Monitoring service
- Patient leaflet
- Monitoring request form with guide
- BLT backgrounder
- BLT case-based monographs
- BLT case-based monograph slide resource
- BLT leave pieces with supporting guides
- Pdfs and working files for all materials

EUTOS for CML



European Treatment and Outcome Study

Core resource

- Introduction to EUTOS for CML
- Discussion guides
- Backgrounders – BLT
- Example PR materials
- Flyers/ Posters/ FAQ

EUTOS for CML



European Treatment and Outcome Study

Pocket card: ELN recommendations



Management of chronic myeloid leukemia (CML):
recommendations from the European LeukemiaNet (ELN)

Definitions of failure, suboptimal response, warnings and optimal response

Table 1. Proposed criteria for failure, suboptimal response, and warnings for previously untreated patients with early chronic phase CML who are treated with imatinib 400 mg daily

Time	Failure	Suboptimal response	Warnings	Optimal response
Diagnosis	N/A	N/A	High risk, del19q+, ACAs in Ph+ cells	N/A
3 months after diagnosis	No HR (stable disease or disease progression)	Less than CHR	N/A	CHR
6 months after diagnosis	Less than CHR, no CgR (Ph+ > 95%)	Less than PCgR (Ph+ > 35%)	N/A	At least PCgR (Ph+ ≤ 35%)
12 months after diagnosis	Less than PCgR (Ph+ > 35%)	Less than CCgR	Less than MMolR	CCgR
18 months after diagnosis	Less than CCgR	Less than MMolR	N/A	MMolR
Any time	Loss of CHR* Loss of CCgR† Mutation‡	ACA in Ph+ cells§ Loss of MMolR§ Mutation#	Any rise in transcript level Other chromosomal abnormalities in Ph- cells	N/A

N/A, not applicable; ACA, additional chromosomal abnormalities; HR, hematologic response; CCgR, complete cytogenetic response; PCgR, partial CgR;

* To be confirmed on two occasions unless associated with progression to accelerated phase/blast crisis;
† To be confirmed on two occasions unless associated with CHR loss or progression to accelerated phase/blast crisis;

‡ High level of insensitivity to imatinib;

§ To be confirmed on two occasions unless associated with CHR or CCgR loss;

Low level of insensitivity to imatinib

- For download at:
<http://www.leukemianet.eu/>
- At the registration desk

EUTOS for CML



European Treatment and Outcome Study

Exhibition booth: EHA 2008

ELN European LeukemiaNet
EU-funded Network of Excellence
www.leukemianet.eu

STRUCTURE

SCOPE
The ELN brings together

- 95 national leukemia study groups
- 102 interdisciplinary partner groups
- 1000 physicians and scientists in
- 147 centers and 28 countries
- caring for tens of thousands of patients

GOALS

- Strengthen scientific and technological excellence with the ultimate goal to cure leukemia
- Develop communication and information structures
- Spread excellence for educational activities, meetings, newsletters and publications
- Prepare guidelines
- Promote clinical trials

CML REGISTRY

- Determine demographic, geographic and ethnic variations
- Evaluate quality-controlled outcomes and implementations of ELN recommendations
- Develop a comprehensive prognostic model

STANDARDISED MOLECULAR MONITORING

- Provide quality-controlled outcome data
- Distribute standardised RQ-PCR for BCR-ABL quantification and mutation detection
- Determine prognostic significance of mutations

PHARMACOLOGICAL MONITORING

- Provide standardized intrablood level testing throughout Europe
- Establish national reference centers
- Define intrablood therapeutic threshold and toxic dose

SPREAD OF EXCELLENCE

- Provide information on CML
- Monitor implementation of ELN guidelines
- Monitor information and communication systems, newsletters, CML systems

CURRENT RESEARCH

Diagnosics
Morphology and immunology
Cytogenetics
Minimal residual disease
Gene profiling

New Treatments
Clinical Trials
Stem cell transplantation
Supportive Care

Epidemiology and Outcome
Registers of in-study and out-study patients
and population based

HIGHLIGHTS

- Establishment of international, communication-oriented structures for an information center and a management center for clinical trials and an ELN website and Internet resources
- European LeukemiaNet Registry in accordance with the International Committee of Medical Journal Editors and the World Health Organization
- European registers for CML, ALL, CLL and MDS
- Clinical trials in European lead in CML, MDS, MDS/PL, CLL, mature B-ALL, Burkitt lymphoma and AML in the interim
- Quality control trials and consensus recommendations as a basis for molecular monitoring in CLL, ALL and morphological response analysis in CLL and morphological response analysis in CLL and morphological response analysis in CLL, ALL, MDS and MDS/PL
- Standardized BCR-ABL, transcripts and for response analysis, for disease monitoring, prognostic and empirical analysis in leukemia patients
- Launch of a new ELN newsletter
- Launch of CML, Burkitt lymphoma and MDS newsletters
- ELN for CML and MDS

CONTACT

Network Management Center
Tel: +49 (0)621 383 4788
E-mail: network@leukemianet.org
www.leukemianet.eu

Planned ASH 2008, DGHO/ÖGHO/SGHO 2008, EHA 2009.

EUTOS for CML



European Treatment and Outcome Study

EUTOS for CML website

The screenshot displays the EUTOS for CML website interface. At the top, the logo 'EUTOS for CML' is shown next to the text 'European Treatment and Outcome Study'. Below this is a navigation bar with links for 'Registry', 'Molecular Monitoring', 'Pharmacological Monitoring', and 'Spread of Excellence'. A left sidebar contains a menu with items: 'About the alliance', 'Objectives', 'News', 'Contact', 'Members only', 'Press & Media', 'Links', and 'Calendar'. The main content area features a 'News' section with two entries: one dated 2008/06/19 about a meeting in Cannes, France, and another dated 2008/05/27 about a workshop in Heidelberg, Germany. An 'Events' section lists several upcoming conferences, including the 20th Meeting of the European Association for Cancer Research, the 33rd ESMO Congress, a conference on Myeloproliferative Disorders, the 50th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, and a joint meeting of DGHO, ÖGHÖ, and SGMÖ. A search bar and the LeukemiaNet logo are visible on the right. At the bottom, a paragraph describes EUTOS as a collaboration between ELN and Novartis to improve CML treatment outcomes, followed by a bullet point for 'CML registry'.

www.eutos.org

EUTOS for CML



European Treatment and Outcome Study

Website contents

- Overview of EUTOS for CML
- Media information
- Dedicated areas for each subproject
- Meetings calendar
- News
- Links

EUTOS for CML



European Treatment and Outcome Study

Spread of Excellence in 2008

- EUTOS FOR CML European event, Cannes, 17-19 October 2008
- An abstract focusing on the EUTOS for CML initiative has been submitted for the DGHO Congress (11–14 October 2008)
- Supportive materials
 - Next editions of ELN newsletter planned for July 2008
 - ELN recommendations update planned for December 2008
 - New poster and flyers

EUTOS for CML

EUTOS for CML

European event

- Cannes, France
- 17–19 October 2008
- Plenary session with interactive voting system and clinical cases discussion
- EUTOS for CML mini booth session: meet the experts at the booth with F. Cervantes, F. Pane
- Preliminary news from EUTOS for CML

EUTOS for CML



European Treatment and Outcome Study

EUTOS EDUCATIONAL DAY FOR FELLOWS

- SoE New idea!!!
 - Eutos educational day for young physicians, researchers, registrars: 1 or 2 participants for each ELN institution will have the opportunity to attend an educational day with ELN top speakers, interactive case discussions, courses on English public speaking etc etc : attendance supported with EUTOS funds.

EUTOS for CML



European Treatment and Outcome Study

Media update

- Very successful launch event held in Budapest, October 2007
- 12 journalists attended this exciting event
- To date (mid-December 2007), over 200 journalists logged onto the webcast
- 20 articles published to date
- Total circulation of 2,000,000+ across nine markets

EUTOS for CML



European Treatment and Outcome Study

Coverage generated



Oncología
Primera alianza europea para el abordaje de la leucemia mieloide crónica
MEDICAL TRIBUNE ONLINE
SONIA GARDE | GM ENVIADA ESPECIAL AL PERIÓDICO (JUNES) A
Fecha de publicación: Domingo, 28 de Octubre de 2007

Santa alleanza contro la leucemia

Maxi-investimento della Novartis, che mette in rete 120 centri di ricerca in 22 paesi di tutto il mondo per dare la spallata definitiva a questo male per il quale i farmaci ormai esistono ma sono difficili da gestire



INDUSTRIA FARMACÉUTICA
Novartis y European LeukemiaNet trabajarán en la mejora del tratamiento de la leucemia mieloide crónica

Industria
Novartis y European LeukemiaNet trabajarán juntos para mejorar el tratamiento de la leucemia mieloide crónica

Αισιοδοξία για την εξέλιξη της νόσου με τα νέα φάρμακα



Settimanale Milano Direttore: Ferruccio de Bori
COOPERAZIONE DALLA RICERCA ALLA CURA
Accordo europeo sulla leucemia

Η Novartis αρωγό ευρωπαϊκά προγρ



iaNet anuncian la creación de EUTOS dos terapéuticos en pacientes con



ONCOLOGY INTERNAL NEWS
European LeukemiaNet and Novartis Oncology Collaborate to Raise Standards for Treating CML in EU
The European LeukemiaNet (ELN) has joined with Novartis Oncology to launch the European Treatment and Outcome Study (EUTOS) for chronic myeloid leukemia (CML).
[more >](#)

EU-WEIC ALLIANZ
Eine Kooperation auf europäischer Ebene soll die Behandlung der mehr als 5.000 Patienten mit chronisch myeloischer Leukämie (CML) europaweit optimieren.
TEXT DR. SUSANNE SCHNEIDER-VOSS

Ja e possível viver com LEUCEMIA

Az ELN és a Novartis útjára indította az ETOS-t
2007. november 12. 20:21, hétfő - [Krasznai Éva](#)



ESTAR VIVO COM...
...Leucemia Mielóide Crónica (LMC)

EUTOS for CML



European Treatment and Outcome Study

EUTOS for CML PR plan for 2008: Maintaining Momentum

- Pan European press event in Cannes the 17th of October with the objective of:
 - Maintain flow of information to key audiences
 - Identify, create and maximise key news milestones, 1 year of Eutos!
 - Provide inspiring materials to be used at countries level: 1st Eutos happy birthday!

EUTOS for CML



European Treatment and Outcome Study